This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MASI Stock Gains Following Q4 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Masimo's fourth-quarter 2024 results continue to benefit from the strength in its Healthcare and Non-healthcare businesses.
Here's Why ResMed (RMD) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in Afterhours
by Zacks Equity Research
ALC's performance is driven by robust demand for its innovative products, balanced geographic footprint and strong execution by the team.
HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket
by Zacks Equity Research
Henry Schein's fourth-quarter results reflect stable dental and medical end-markets.
HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin Contracts
by Zacks Equity Research
Hims & Hers' revenue channels witness strong growth on the back of solid product demand in the fourth quarter.
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
by Zacks Equity Research
Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.
AMN Stock Gains Following Q4 Earnings & Revenues Beat, Margins Down
by Zacks Equity Research
AMN Healthcare's dismal results in the majority of its segments led to a soft overall fourth-quarter performance.
ITGR Stock Declines Following Q4 Earnings Miss, Gross Margin Contract
by Zacks Equity Research
Integer Holdings' fourth-quarter results reflect robust sales from the majority of the product lines, along with continued product adoption.
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise
by Zacks Equity Research
Insulet's fourth-quarter results benefit from the continued high demand for Omnipod 5.
Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips
by Zacks Equity Research
GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger.
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
ICLR Q4 Earnings and Revenues Beat, Stock Rises at After-Market
by Zacks Equity Research
ICON's fourth-quarter 2024 earnings and revenues beat estimates as it manages to navigate a challenging transition period.
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y
by Zacks Equity Research
Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
by Zacks Equity Research
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
by Zacks Equity Research
Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles
by Zacks Equity Research
MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins.
BIO Stock Might Rise Following the Offer to Acquire Stilla
by Zacks Equity Research
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
by Zacks Equity Research
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall
by Zacks Equity Research
Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments.
DVA Stock Down in Pre-Market Despite Q4 Earnings Beat, Margins Expand
by Zacks Equity Research
Robust segmental revenues drive DaVita's fourth-quarter 2024 performance despite a per-day decrease of the total U.S. dialysis treatments on a sequential basis.
Here's Why ResMed (RMD) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
ResMed (RMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls
by Zacks Equity Research
Bruker delivers better-than-expected earnings and revenues in the fourth quarter of 2024.